Anti-atherosclerotic effects and molecular targets of ginkgolide B from <i>Ginkgo biloba</i>.

Authors:
Ye W; Wang J; Little PJ; Zou J; Zheng Z and 8 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.09.014

PMCID:
PMC10792990

PMID:
38239238

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation o…
Wang M; Wang W; You S and 6 more (2023) - Transparency Score: 3/6
Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of …
Sun X; Xu X; Wang J and 8 more (2023) - Transparency Score: 3/6
Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer t…
Xie Q; Chu Y; Yuan W and 7 more (2023) - Transparency Score: 3/6
Activation of PXR causes drug interactions with Paxlovid in transgenic mice.
Lei S; Guo A; Lu J and 4 more (2023) - Transparency Score: 3/6
Adiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal …
Pham DV; Nguyen TK; Nguyen BL and 4 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors declare no conflict of interests."

Evidence found in paper:

"This work is supported by 10.13039/501100001809National Natural Science Foundation of China (82270500, 81870324, 82203304, 82070464, U1401225, U21A20419); National Mega-Project for Innovative Drugs (2019ZX09735002); Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01Y036, 2017BT01Y093, China); National Engineering and Technology Research Center for New drug Druggability Evaluation (Seed Program of Guangdong Province, 2017B090903004, China)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025